赛升药业:2025一季报净利润0.4亿 同比增长120.94%

Financial Performance - The company reported a basic earnings per share of 0.0830 yuan for Q1 2025, a significant increase of 120.98% compared to a loss of 0.3957 yuan in Q1 2024 [1] - Net profit for Q1 2025 was 0.4 billion yuan, recovering from a loss of 1.91 billion yuan in Q1 2024, marking a 120.94% increase [1] - Operating revenue decreased to 0.93 billion yuan in Q1 2025, down 15.45% from 1.1 billion yuan in Q1 2024 [1] - The return on equity (ROE) improved to 1.18% in Q1 2025 from -5.71% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 77.25 million shares, accounting for 28.22% of the circulating shares, with a decrease of 1.8142 million shares compared to the previous period [1] - Major shareholders include Ma Qiao with 59.62 million shares (21.77%), and Ma Li with 7.46 million shares (2.73%), both remaining unchanged [2] - New entrants among the top shareholders include Goldman Sachs and Morgan Stanley, while several previous shareholders have exited the top ten list [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]